BIOTRAK™ REAL-TIME VIABLE PARTICLE COUNTER - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BIOTRAK™ REAL-TIME VIABLE PARTICLE COUNTER

A real-time viable particle counter such as the TSI BioTrak™ detector can continuously monitor an aseptic process for airborne viable particles, and per the current GMP guidance, monitor total particle counts simultaneously using an existing single particle monitoring probe. Data is logged and alarms generated in real-time using a Facility Monitoring System. No need to intervene and cleanup following a plate change or load growth media into the isolator, no need to add additional interfaces. If there is a microbiological excursion, everyone will know right away..

In a single portable instrument the TSI BioTrak™ Real-time viable particle detector counts airborne particles compliant to ISO 21501-4and has a 28.3 lpm sample flow rate. It then analyzes each particle for viability, finally it collects all optically analyzed particles on a collection filter to enable laboratory based speciation analysis. BioTrak™ – the real-time viable particle counter that delivers airborne viable particle count data you can trust, moving you towards real-time quality assurance and process control.

Contact TSI (www.tsi.com) today to arrange an evaluation and find out more about the many immediate use applications the BioTrak detector has to offer. Gain a competitive advantage today, the potential benefits this technology has to offer are too great to ignore.

Further information on Biotrak visit: www.tsi.com/biotrak-9510 or E-Mail: emea.tsi@tsi.com

About TSI Incorporated

TSI Incorporated serves a global market by investigating, identifying and solving measurement problems. As an industry leader in the design and production of precision instruments, TSI partners with research institutions and customers around the world to set the standard for measurements relating to aerosol science, air flow, health and safety, indoor air quality, fluid dynamics and biohazard detection.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
FindPharma Custom Search

Click here